Table 1. Baseline characteristics of SOT recipients with COVID-19.
| Variables | n = 41 (%) |
|---|---|
| Median age, years, IQR | 58 (33–86) |
| Male sex | 27 (66) |
| Transplanted organ | |
| Kidney | 32 (78) |
| Liver | 4 (10) |
| Heart | 3 (7) |
| Combined liver-kidney transplant | 2 (5) |
| Underlying conditions | |
| Hypertension | 33 (81) |
| Diabetes mellitus | 34 (83) |
| Cardiovascular disease | 10 (24) |
| COPD | 8 (20) |
| Chronic kidney disease | 14 (34) |
| Years from transplant to diagnosis, median (IQR) | 6 (1–21) |
| Immunosupressive regimen | |
| Calcineurin inhibitors based therapy | 26 (63) |
| mTOR based therapy | 15 (37) |
| Previous episodes of acute rejection (3 months, only biopsy proven) | 0 |
| COVID-19 adjuvant treatment | |
| Lopinavir/ritonavir | 31 (76) |
| Hydroxychloroquine | 40 (98) |
| Remdesivir | 0 |
| Azithromycin | 41 (100) |
| Tocilizumab | 19 (46) |
| Anakinra | 7 (17) |
| Baricitimib | 1 (2) |
| Steroids pulse | 17 (41) |
| Interferon | 3 (7) |
*COPD: Chronic obstructive pulmonary disease.